AIM

Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

Retrieved on: 
Friday, February 16, 2024

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion. AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response. Iovance is also conducting TILVANCE-301, a Phase 3 trial to confirm clinical benefit.

Key Points: 
  • This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response.
  • AMTAGVI is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer.
  • “Given the significant unmet needs in the advanced melanoma community, we are proud to offer a personalized, one-time therapeutic option for these patients.
  • Iovance will host a conference call and live audio webcast today to discuss the FDA approval of AMTAGVI.

Piedmont Lithium to Release Fourth-Quarter & Full-Year 2023 Results on February 22, 2024

Retrieved on: 
Thursday, February 15, 2024

Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced that it will release its fourth-quarter and full-year 2023 earnings following the Nasdaq close on Thursday, February 22, 2024.

Key Points: 
  • Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced that it will release its fourth-quarter and full-year 2023 earnings following the Nasdaq close on Thursday, February 22, 2024.
  • The Company will hold a conference call to discuss fourth-quarter and full-year 2023 results on Thursday, February 22, 2024, at 4:30 p.m. Eastern Time (U.S. and Canada).
  • Our goal is to become one of the largest lithium hydroxide producers in North America by processing spodumene concentrate produced from assets where we hold an economic interest.
  • Our projects include our Carolina Lithium and Tennessee Lithium projects in the United States and partnerships in Quebec with Sayona Mining (ASX: SYA) and in Ghana with Atlantic Lithium (AIM: ALL; ASX: A11).

Advyzon Investment Management (AIM) Partners with Nebo Wealth to Create Turnkey, End-to-End Solution

Retrieved on: 
Thursday, February 15, 2024

Advyzon Investment Management (AIM), a turnkey asset management program (TAMP) under the umbrella of comprehensive technology platform Advyzon , recently announced a partnership with Nebo Wealth , an award-winning asset allocation and portfolio design platform from global asset manager Grantham, Mayo, Van Otterloo & Co., LLC (GMO).

Key Points: 
  • Advyzon Investment Management (AIM), a turnkey asset management program (TAMP) under the umbrella of comprehensive technology platform Advyzon , recently announced a partnership with Nebo Wealth , an award-winning asset allocation and portfolio design platform from global asset manager Grantham, Mayo, Van Otterloo & Co., LLC (GMO).
  • AIM now powers and serves as a turnkey platform for Nebo Wealth, an end-to-end solution that enables Registered Investment Advisors (RIAs) to streamline and automate the process of delivering personalized portfolios for each and every client at scale.
  • “Nebo Wealth represents a leap forward in goals-based wealth management and the future of personalized portfolios,” said Martin Tarlie, Product Lead at Nebo Wealth.
  • To learn more about Advyzon Investment Management, please click here .

Bango and Sam Media power extended reality (XR) subscription bundles for telcos

Retrieved on: 
Thursday, February 15, 2024

CAMBRIDGE, United Kingdom, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bango (AIM:BGO) is pleased to announce the expansion of its partnership with Sam Media to offer its extended reality (XR) subscription services through the Digital Vending Machine® (DVM™).

Key Points: 
  • CAMBRIDGE, United Kingdom, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bango (AIM:BGO) is pleased to announce the expansion of its partnership with Sam Media to offer its extended reality (XR) subscription services through the Digital Vending Machine® (DVM™).
  • Resellers, such as telcos, that have standardized on the Digital Vending Machine® to bundle subscriptions, can now add Sam Media's XR content to their consumer offers.
  • Sam Media's groundbreaking technology makes XR content accessible to everyone, irrespective of their device, eliminating the need for costly equipment.
  • Among the XR content offerings is SingSpace, powered by Stingray Karaoke - a virtual reality platform redefining the karaoke experience.

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

Retrieved on: 
Wednesday, February 14, 2024

The primary objective of the Phase 2 portion is to determine the clinical benefit rate of the combination therapy.

Key Points: 
  • The primary objective of the Phase 2 portion is to determine the clinical benefit rate of the combination therapy.
  • Subjects will start with Ampligen 200 mg via IV infusion twice per week for a total of 6 weeks (12 doses).
  • The first dose of Ampligen will be administered preferably 4-6 weeks after the last chemotherapy FOLFIRINOX dose.
  • After two doses of Ampligen, the first dose of durvalumab 1500 mg via IV infusion will be introduced in week 2.

Impulse Dynamics Completes $136M Financing Round

Retrieved on: 
Wednesday, February 14, 2024

The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare.

Key Points: 
  • The financing was led by Perceptive Advisors, Redmile Group, Alger, and Hobart Healthcare.
  • This substantial investment reflects investor confidence in, and commitment to, the company’s vision and expansion.
  • “This round of funding will accelerate our business, both commercially and with our pipeline of advanced technology innovation,” said Jason Spees, CEO of Impulse Dynamics.
  • “We are thrilled by the ongoing support from top-tier investment groups for Impulse Dynamics,” said Shlomi Nachman, Chairman of the Board.

Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting

Retrieved on: 
Tuesday, February 13, 2024

BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company, today announced it is highlighting recently-launched products in high growth segments of joint preservation and restoration from its Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions businesses during the 2024 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting on February 13-15 in San Francisco, CA. Throughout the event, Anika will feature its differentiated shoulder portfolio including the recently launched Integrity Implant System for rotator cuff repair, RevoMotion Reverse Shoulder Arthroplasty (RSA) System with newly launched AIMTM (Anika Implant Management) surgical planning software, X-Twist Fixation System with biocomposite suture anchor, OVOMotion® with Inlay Glenoid Total Shoulder Arthroplasty (TSA) System, and many more of its early intervention orthopedic solutions, in booth #5145.

Key Points: 
  • “Anika is excited to highlight our recently launched Integrity Implant System, our newest regenerative hyaluronic acid (HA)-based scaffold for rotator cuff repair, and our X-Twist Fixation System with biocomposite suture anchor.
  • We have also enhanced our shoulder arthroplasty offerings with the launch of AIM, Anika Implant Management, for 3-D preoperative planning which is now available with both the RevoMotion Reverse Shoulder and OVOMotion Total Shoulder arthroplasty systems.
  • The RevoMotion Reverse Shoulder Arthroplasty System, with the industry’s smallest diameter threaded baseplate, offers surgeons and patients the ability to restore motion and preserve bone.
  • Several new Sports Medicine products will also be available in early 2024, including the ProPass™ Suture Passer, and other new shoulder instrumentation.

Results of Fundraising

Retrieved on: 
Tuesday, February 13, 2024

Such restrictions shall not apply to any Fundraising Shares acquired outside of Canada.

Key Points: 
  • Such restrictions shall not apply to any Fundraising Shares acquired outside of Canada.
  • This Announcement does not constitute a recommendation concerning any investor's options with respect to the UK Placing or any part of the Fundraising.
  • The Fundraising Shares to be issued pursuant to the Fundraising will not be admitted to trading on any stock exchange other than AIM, the TSX-V and Nasdaq Iceland’s main market.
  • The actual results, performance or achievements of the Company or developments in the industry in which the Company operates may differ materially from the future results, performance or achievements or industry developments expressed or implied by the forward-looking statements contained in this Announcement.

OTC Markets Group Welcomes Serabi Gold Plc to OTCQX

Retrieved on: 
Monday, February 12, 2024

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Serabi Gold Plc (AIM: SRB; TSX: SBI; OTCQX: SRBIF), a Brazilian-focused gold mining and development company, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Serabi Gold Plc (AIM: SRB; TSX: SBI; OTCQX: SRBIF), a Brazilian-focused gold mining and development company, has qualified to trade on the OTCQX® Best Market.
  • Serabi Gold Plc upgraded to OTCQX from the Pink® market.
  • Serabi Gold Plc begins trading today on OTCQX under the symbol “SRBIF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • Serabi’s CEO, Mike Hodgson commented, “We are delighted to qualify for the premier tier on OTC Markets.

Commencement of Trading on OTCQX

Retrieved on: 
Monday, February 12, 2024

Serabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to announce that its ordinary shares are now trading on the OTCQX under the ticker symbol of SRBIF.

Key Points: 
  • Serabi Gold plc (AIM:SRB, TSX:SBI), the Brazilian-focused gold mining and development company, is pleased to announce that its ordinary shares are now trading on the OTCQX under the ticker symbol of SRBIF.
  • The OTCQX is the highest market tier of OTC Markets on which global securities trade.
  • Trading on OTCQX will enhance the visibility, liquidity and accessibility of the Company to U.S. investors.
  • Securing a quotation on OTCQX will simplify the ability for US based investors to invest in Serabi’s ordinary shares without the need to establish trading accounts in either the UK or Canada.